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Abstract
Background—Extended follow up of statin-based low density lipoprotein (LDL) cholesterol 
lowering trials improves understanding of statin safety and efficacy. Examining cumulative 
cardiovascular events (total burden of disease) gives a better appreciation of the clinical value of 
statins.  This paper evaluates the long-term impact of therapy on mortality and cumulative 
morbidity in a high risk cohort of men. 
Methods and Results—The West of Scotland Coronary Prevention Study was a primary 
prevention trial in 45-64 year old men with high LDL cholesterol. 6595 men were randomized to 
receive pravastatin 40mg once daily or placebo for an average of 4.9 years. Subsequent linkage 
to electronic health records permitted analysis of major incident events over 20 years. Post-trial 
statin use was recorded for 5 years post-trial, but not the last 10. Men allocated to pravastatin had 
reduced all-cause mortality; hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.80-0.94, 
p=0.0007, mainly attributable to a 21% decrease in cardiovascular death; HR 0.79 (CI 0.69-
0.90), p=0.0004. There was no difference in non-cardiovascular or cancer death rates between 
groups. Cumulative hospitalisation event rates were lower in the statin treated arm: by 18% for 
any coronary event (p=0.002), 24% for myocardial infarction (p=0.01) and 35% for heart failure 
(p=0.002). There were no significant differences between groups in hospitalization for non-
cardiovascular causes. 
Conclusions—Statin treatment for five years was associated with a legacy benefit with improved 
survival and a substantial reduction in cardiovascular disease outcomes over a 20-year period, 
supporting the wider adoption of primary prevention strategies. 
 
Key words: coronary heart disease; clinical trial; primary prevention; heart failure; safety; 
epidemiology; lipids
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Introduction 
Lowering of low density lipoprotein (LDL) cholesterol is accepted as a key objective in the 
prevention of cardiovascular disease.1,2 Controversies remain, however, as to which kind of 
subjects to treat, use of goals, the magnitude of the benefit, and potential harms especially in the 
context of primary prevention.3-6  Examination of the long-term (lifetime) consequences of 
lowering LDL cholesterol can assist greatly in understanding more fully the efficacy and safety 
of this intervention, and a number of studies have reported extended observations beyond the end 
of the formal trial.7-11  In the West of Scotland Coronary Prevention Study (WOSCOPS), where 
follow-up was first examined  approximately 10 years after the end of the 5 year trial7, there was 
evidence of further reduction in coronary events over the 15 year period and, based on the 
available data, no emergent safety issues.  Overall, there was a reduction in all-cause mortality 
(hazard ratio (HR) = 0.88, 95% confidence interval (CI) (0.79–0.99), p=0.03) and in the outcome 
of death or hospitalisation due to coronary heart disease (HR=0.75, 95% CI (0.68–0.83), 
p<0.001). Further, over the 15 year period, five years of treatment with pravastatin was shown to 
be cost-saving in terms of overall health service costs12, adding an important economic 
dimension to the clinical outcome analysis. Previous work had shown there was a relatively low 
uptake of statin treatment in the first five years of extended follow-up after the trial, which 
means WOSCOPS is uniquely placed to investigate the legacy effects of five years of statin 
treatment in terms of ongoing benefit and potential safety issues later in life.  
We have now increased the period of follow-up to 20 years to examine a range of 
mortality and morbidity outcomes as a ‘first event’ and as a ‘total burden of disease’ in the form 
of cumulative hospital admissions. More detailed interrogation of hospitalisation rates has 
allowed a fuller picture of benefits and risks to emerge. Given a mean age at randomisation of 55 
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years, the extended observation period - to a mean of 75 years (range 65-85 years) - gives an 
approximation of the lifetime benefit of this pharmacological intervention. 
Methods
The design of WOSCOPS and its long-term follow-up have been described elsewhere.13-15  It 
was a randomised trial of pravastatin (40mg once daily) versus placebo in  men, aged 45-64 
years (mean age 55 years), with raised cholesterol who had no evidence of previous myocardial 
infarction (based on medical history and a baseline, centrally-read electrocardiogram). 
Participants had a mean (SD) plasma cholesterol level of 272 (23) mg per deciliter (7.0 (0.6) 
mmol per liter) and a mean (SD) LDL cholesterol level of 192 (17) mg per deciliter  (5.0 (0.44) 
mmol per liter), 44% were current smokers, 16% had a history of hypertension, and 1% had a 
history of diabetes.  Between 1989 and 1991, 6595 men gave written informed consent and were 
enrolled in the trial. The average follow-up was 4.9 years (range, 3.5 to 6.1years) with final study 
visits in May 1995. 
After the end of the trial, use of lipid-lowering therapy during the first 5 years of 
extended follow-up was monitored by review of case records; in the original pravastatin and 
placebo groups respectively, 28.6% and 24.3% at 1 year post-trial, 33.6% and 29.4% at 3 years, 
and 38.7% and 35.2% at 5 years were found to be on statins.7 No further data on statin treatment 
was available after this point. Extended follow-up for clinical events was based entirely on 
linkage to national electronic hospital discharge records held by the Information Services 
Division in Edinburgh, the Scottish Cancer Registry and the Scottish General Register Office 
death records by means of established methods.16,17   Data were extracted  from trial 
commencement to  October 2011 and classified using International Classification of Diseases 
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(ICD) codes and Office of Population, Censuses and Surveys Classification of Surgical 
Operations and Procedures (OPCS) codes. Cancer Registry Data were only available until 
November 2010.   
The original trial was approved by the Ethics committees of the University of Glasgow 
and participating health boards in Scotland and the long-term follow-up and associated record 
linkage by the Ethics committee of the Royal Infirmary, Glasgow and the Privacy Advisory 
Committee of the National Health Service for Scotland.  All participants gave informed consent 
to take part in the trial and to the examination of their medical records. 
Previous analyses focussed on time-to-first event for deaths, incident cancers and 
composite cardiovascular outcomes7,14 and health economics evaluation.12  In the current report 
we assessed the impact on mortality, incident cancers and the cumulative number of hospital 
admissions over 20 years or until death.  We report on hospital admissions for each of non-
cardiovascular causes, cardiovascular causes, coronary heart disease, myocardial infarction, heart 
failure, stroke and we describe the cumulative number of coronary revascularisations (coronary 
artery bypass graft or percutaneous coronary intervention or angioplasty). 
Statistical methods 
Cumulative incidence functions, accounting for the competing risk of death from other causes, 
were used to describe the incidence of cause-specific deaths or time to first incident cancer.  To 
estimate treatment effects for cause-specific mortality and incident cancers Cox proportional 
hazards models were fitted including the treatment group and baseline risk factors - age, body 
mass index, systolic and diastolic blood pressures, high and low-density lipoprotein cholesterol 
levels, log-transformed triglyceride level, nitrate use, history of angina, history of diabetes, 
history of hypertension (all yes or no), smoking status (current, former, never), and a seven 
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category social deprivation score.18 Treatment effects (pravastatin versus placebo) were 
expressed as hazard ratios with 95% confidence intervals and corresponding p-values.  
The cumulative numbers of hospital admissions of each type were presented, without 
adjustment for the competing risk of death, to represent the true difference in health care 
resource usage over 20 years (all participants had a potential follow-up of a minimum of 20 
years). We also calculated the crude rates of hospital admission of each type correcting for the 
different total periods of follow-up in each randomised group due to the increased survival and 
consequent greater exposure to risk in the statin treated group. These statistics were compared 
using re-randomisation tests (based on 10,000 re-randomisations). 
Because of the interest in the long term impact of statin treatment on diabetes and its 
complications, we identified all non-cardiovascular hospital admissions that were associated with 
diabetes or its complications, either as a reason for admission or as a factor complicating the 
admission. Cardiovascular admissions were omitted from this analysis because of the potential 
bias associated with the overall reduction in cardiovascular admissions due to statin treatment.  
Similarly we reported on other non-cardiovascular hospital admissions grouped by ICD-10 codes 
to examine the long-term safety of statin use. These analyses were further sub-divided into day-
cases and non day-cases. 
The data analysis for this paper was generated using SAS software, Version 9.3 of the 
SAS System for Windows. Copyright © SAS Institute Inc. SAS and all other SAS Institute Inc. 
product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, 
NC, USA. 
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Results
The mean follow-up until censoring date or death in the pravastatin treated group was 18.6 years 
compared to 18.3 years for the placebo group.  Baseline characteristics of the two randomised 
groups have been reported previously.15  There were no differences in characteristics at baseline 
between the two groups including age, body mass index, blood pressure, cholesterol, alcohol use, 
smoking, employment and previous medical history. 
Mortality
In the total period of follow-up 1253 (38%) of those originally randomised to placebo died 
compared to 1145 (34.7%) in the pravastatin group, HR = 0.87, 95% CI 0.80 – 0.94, p=0.0007. 
There were also reductions in cardiovascular mortality, HR = 0.79, 95% CI 0.69 – 0.90, 
p=0.0004 and coronary mortality (HR = 0.73, 95% CI 0.62 – 0.86, p=0.0002), but not for stroke. 
There was no evidence of an increased risk of non-cardiovascular or cancer mortality in the 
pravastatin group. (Table 1, Figures 1a-d, Supplementary Figure 1a) 
Incident cancers 
There was no evidence of an increased risk of overall incident cancer, 809 (24.6%) participants 
had events in the placebo treated group compared to 802 (24.3%) on pravastatin (p = 0.24), or of 
cause-specific cancers (Supplementary Table 1, Supplementary Fig 1b). 
Cumulative hospital admissions 
In the group of 3293 participants originally randomised to placebo, 1546 experienced a total of 
4102 cardiovascular admissions compared to 1398 participants (out of 3302) in the pravastatin 
group who had 3436 admissions, p < 0.0001 (Table 2, Fig 2a). Similarly there were significant 
reductions in recurrent coronary (p = 0.0006), myocardial infarction (p = 0.0002) and heart 
failure admissions (p=0.01) (Supplementary Fig 2a, Figs 2b, 2c), but not for stroke 
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(Supplementary Fig 2b). There was a significant reduction in hospital admissions involving 
coronary revascularisation (percutaneous coronary intervention, coronary artery bypass surgery 
or angioplasty) with 1210 events in the placebo group and 1029 in the pravastatin group, p = 
0.0078 (Fig 2d).  
There were numerically more non-cardiovascular admissions in the pravastatin group but 
the rates when adjusted for duration of follow-up were similar, 2.97 events/10 years for placebo 
compared to 3.03 events/10 years for pravastatin. Neither comparison achieved statistical 
significance.  (Table 2, Supplementary Fig 2c). 
In a further exploration, hospitalisations were divided into day-cases and non-day cases 
(that is, events involving an overnight stay). Subjects in the pravastatin group had fewer 
hospitalisations for cardiovascular reasons in both categories (Table 3).  Supplementary tables 
2 and 3 give the frequency of non-cardiovascular admissions by ICD body system classification 
for day cases and non day-cases. Overall, the numbers of subjects and cumulative events were 
balanced between the two groups for non day-cases. For day-cases it was noted that the 
pravastatin group had an apparent increased risk of events associated with diseases of the eye 
and adnexa (p=0.03 uncorrected for multiple comparisons) which was attributable for the most 
part to an excess of admissions for cataract surgery (not individually statistically significant). 
There were numerically more day-case events but not subjects with events associated with 
neoplasms and diseases of the digestive system.  
Hospital admissions associated with complications of diabetes 
In the placebo group, a total  of 221 participants experienced 911 non-cardiovascular hospital 
admissions that contained a diabetes related ICD code compared to 201 participants (770 
admissions) in the pravastatin treated group; hazard ratio 0.81, 95% CI 0.67 – 0.98, p = 0.030. 
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For hospital admissions involving complications of diabetes, 29 participants in the placebo group 
experienced 80 admissions compared to 12 participants (44 admissions) in the pravastatin treated 
group; hazard ratio 0.33, 95% CI 0.16 – 0.66, p = 0.0016.  There were 23 deaths with a cause of 
death given as diabetes (15 on placebo and 8 on pravastatin). 
Discussion
This 20 year follow up of the West of Scotland Coronary Prevention Study identified a continued 
legacy benefit from 5 years of LDL cholesterol lowering with a statin through improved survival 
due to decreased mortality from cardiovascular causes and ongoing reduction in cardiovascular 
hospital admissions.  Cumulative event rates are presented for both treatment arms to assess the 
impact of therapy on the total burden of disease.  We observed a substantial and significant 
benefit; cumulative event rates were 18% lower for cardiovascular disease and 24% lower for 
myocardial infarction in the pravastatin group.  Our focus on recurrent events reflects current 
interest in the impact of interventions on the total burden of disease. We observed also 
continuing divergence of the cumulative event curves for heart failure hospitalisation over 20 
years with a 35% lower rate in the pravastatin arm. 
Over two decades since the publication of the first successful primary prevention trial of 
a statin15, with subsequent studies19,20 and meta-analyses5,21,22 also confirming the benefits of 
LDL cholesterol reduction, there are still concerns over side effects of treatment, long-term 
safety, impact on all-cause mortality, and cost-effectiveness3-6,23,24 that lead a number of 
commentators to continue to express caution when wider use of statins in primary prevention 
strategies is promoted.25,26  The current study found no increased incidence of cancer overall, and 
enhanced site-specific data shows no imbalance between the two groups (note the balanced rates 
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for prostate cancer compared to the previous report).7  Examination of non-cardiovascular 
admissions to hospital also showed no differences with the exception of a possible increased risk 
of day-case hospital admissions associated with diseases of the eye for patients using pravastatin. 
The significance of this latter finding, which should be treated cautiously due to the borderline 
significance and the multiple adverse effects investigated, lies in its link to historical concern that 
inhibition of cholesterol synthesis would be lead to risk of corneal opacity.27,28  Epidemiological 
studies have suggested both increased and decreased risk of cataracts linked to statin use.29-31  
However, these studies will not have the length of follow-up available in WOSCOPS or the 
benefits of randomisation in minimising confounding factors. It should be noted that any 
treatment that improves cardiovascular survival will inevitably result in an increase in hospital 
admissions for non-cardiovascular causes. We saw no evidence of this for non day-case 
admissions. However, the trend to increased day-case admissions including  treatment for cancer  
but not number of participants with cancer, particularly for events associated with advancing age, 
in the later years of follow-up could be early evidence of this survival bias effect. 
Reduction in heart failure as an outcome has been reported recently in a meta-analysis of 
14 trials of statin-based LDL lowering with a risk reduction of 10%.32  The mean duration of 
observation in these studies was 4.3 years. Data presented here suggest that this additional 
clinical benefit may be underestimated in short-term studies particularly in primary prevention. 
As was noted in the report by Preiss et al32 we found that the number of heart failure admissions 
was reduced in subjects who had, and in those who did not have, an antecedent myocardial 
infarction (data not shown). The overall mechanism by which LDL lowering leads to a reduced 
incidence of heart failure is not fully clear. However, we note that much of the WOSCOPS 
follow-up was prior to the use of troponin assays and certainly before newer high sensitive 
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assays. Hence, many of the events classed as other coronary hospitalisations would be today 
classed as myocardial infarction. Likewise, the reduced need for revascularisation in statin 
treated participants indicates lower levels of ischaemia, the repeated occurrence of which could 
be a mechanism for the development of heart failure. 
We did not demonstrate a reduction in stroke at 20 years.  There was no effect in the 
original trial,15 although we did see evidence of stroke reduction in the 15 year follow up.7  
However, WOSCOPS was a primary prevention trial in relatively young subjects compared to 
the majority of trials in the CTTC analysis which were secondary prevention studies in 
participants about 10 years older at randomisation and which had shorter periods of follow-up.22  
It is difficult therefore to compare directly the findings in CTTC with extended observations 
made when the original treatment arms are predicted to be receiving statin therapy at the same 
level after the trial. 
In assessing the long-term impact of interventions in primary prevention, it is essential 
that there is a balanced evaluation of the benefits due to reduction in cardiovascular events and 
the potential for adverse clinical outcomes.  Muscle related side effects of statins have been 
studied in detail.33  They can lead to intolerance to the medication and in rare instances 
rhabdomyolysis.1,2   Statin therapy has been shown also in a number of studies to increase the 
propensity to develop type-2 diabetes34, 35 with a hazard ratio of about 1.09 compared to placebo; 
a similar increment in diabetes risk is associated with the use of high versus low dose statin 
therapy.35  This is one of the issues raised by those concerned with the more widespread use of 
statins in the prevention of disease in lower risk subjects.3-6  Diabetes is defined on the basis of 
blood glucose levels and is a disorder associated with macrovascular but also microvascular/ 
non-cardiovascular complications. Statins reduce cardiovascular disease and it has been 
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estimated that their use will prevent five incidences of myocardial infarction for every new case 
of diabetes.36  In this study we were able to report also that statin treatment was associated over a 
20 year follow up with significantly less hospital admissions associated with non-cardiovascular 
complications of diabetes. This raises the possibility that while statin use may impact on blood 
glucose levels this does not necessarily translate into deleterious non-cardiovascular pathologies. 
It should be noted, however, that WOSCOPS was unusual in that the incidence of type 2 diabetes 
was lower in the actively treated arm during the original trial.37 
There are limitations to this form of long-term follow up based on electronic health 
records as noted previously.7,16  Critically, we do not know what lipid regulating therapy was 
being used by the participants for the last 10 years of the study and this limits interpretation of 
data with regard to the magnitude of the 20-year benefit. If in the second half of the extended 
follow up more subjects originally ascribed to placebo relative to the pravastatin arm were placed 
on a statin (as a result of having a coronary event or as a primary prevention measure by the GP) 
then the difference in event rates between the two groups would be diminished and the observed 
hazard ratio would be an underestimate of the long-term risk reduction attributable to statin 
therapy. Also, we are dependent on the stability of the population to allow comprehensive 
capture of hospitalisations within the healthcare information systems. However, Scotland is an 
area of relatively low social mobility after people reach middle age which allowed us to achieve 
100% follow-up at the end of the study.  We also flagged all of our participants with the death 
registry in England and Wales and  identified only 15 deaths (0.6%) there from a total of 2398 
deaths. We have no current method for identifying hospital admissions outside Scotland but do 
not feel this would have altered our findings.  Finally, as a substantial number of participants die, 
analyses are complicated by competing risks. 
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In conclusion, in this primary prevention trial in high risk men with raised LDL 
cholesterol but without a history of myocardial infarction we observed a long-term legacy benefit 
of LDL lowering by statin therapy. Since over the 20 years the cohort aged from an average of 
55 to 75 years, the cumulative event rate is an estimate of the total burden of disease (more 
specifically of premature morbidity and mortality - male life expectancy in Scotland is 76.8 
years) and the reduction in cardiovascular events a measure of the ‘lifetime’ benefit of the 
intervention. The reduction in cumulative cardiovascular events is substantial both numerically 
(with attendant economic savings) and in terms of relative risk (especially for heart failure). The 
observation that 5 years of statin therapy led to a prolonged risk reduction raises the issue that 
treatment might not need to be lifelong. That is, the legacy risk reduction following say a 5 to 10 
year treatment period may be sufficient to produce a clinically meaningful benefit while limiting 
lifetime exposure to the drug. We cannot address this question fully using the information in the 
current study although it is clear that therapy would have to be maintained for subjects to 
experience maximum risk reduction since we did see a diminution in the treatment effect in the 
post-trial compared to the in-trial phases.  The data on diabetes associated non-cardiovascular 
events indicate that further work is required to understand the clinical consequences of the statin 
induced rise in the incidence of this disorder. These long-term efficacy findings, particularly on 
all-cause mortality, and detailed safety data should allay concerns over strategies to promote the 
more widespread use of statins in the population. 
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Clinical Perspective 
Adoption of statin therapy for primary prevention of cardiovascular disease is an area of 
controversy in clinical practice. There is perceived uncertainty regarding long term efficacy with 
respect to vascular and all-cause mortality, and the long-term safety of treatment. The findings of 
the present study should help alleviate at least some of these concerns. Extended follow up of 
this primary prevention trial in high risk men with raised LDL cholesterol but without a history 
of myocardial infarction demonstrated a long-term ‘legacy’ benefit of LDL lowering by statin 
therapy with a significant reduction in cardiovascular mortality and improved survival when 
viewed over the entire 20 years of follow up. Further, the reduction in cumulative cardiovascular 
events – representing the ‘total burden of disease’ - was substantial both numerically (with 
attendant economic savings) and clinically in terms of relative risk across a range of 
cardiovascular outcomes. The finding of a late post-trial benefit of a reduced risk of heart failure 
gives further impetus to the need to start treatment early. These long-term efficacy findings, 
particularly on all-cause mortality, and detailed safety data should allay concerns over strategies 
to promote the more widespread use of statins in the population. 
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Table 1. Number of events (%) and hazard ratios for pravastatin treatment effect for mortality 
outcomes. 
Placebo (n=3293) Pravastatin ( n = 3302) 
All causes   
Deaths (%) 1253 (38.0) 1145 (34.7) 
Hazard Ratio (95% CI) †  0.87 (0.80, 0.94) 
P-value†  0.0007 
All cardiovascular   
Deaths (%) 496 (15.1) 414 (12.5) 
Hazard Ratio (95% CI) †  0.79 (0.69, 0.90) 
P-value†  0.0004 
CHD   
Deaths (%) 326 (9.9) 252 (7.6) 
Hazard Ratio (95% CI) †  0.73 (0.62, 0.86) 
P-value†  0.0002 
Stroke   
Deaths (%) 86 (2.6) 103 (3.1) 
Hazard Ratio (95% CI) †  1.15 (0.86, 1.53) 
P-value†  0.35 
All non-cardiovascular   
Deaths (%) 757 (23.0) 731 (22.1) 
Hazard Ratio (95% CI) †  0.92 (0.83, 1.02) 
P-value†  0.12 
Cancer   
Deaths (%) 469 (14.2) 468 (14.2) 
Hazard Ratio (95% CI) ±  0.96 (0.84, 1.09) 
P-value±  0.49 
*Excludes participants who died within trial. †Adjusted for age, body mass index, systolic blood pressure, diastolic 
blood pressure, HDL cholesterol, LDL cholesterol, log triglyceride, nitrate use, history of angina, history of 
diabetes, history of hypertension, smoking status (current, ex-smoker, never) and deprivation (DEPCAT).± Adjusted 
for age, body mass index, smoking status (current, ex-smoker, never) and deprivation (DEPCAT).  
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Table 2. Subjects with events, cumulative recurrent events and event rates per 10 years of 
follow-up between randomised groups. 
Event Type Statistic Placebo
(n = 3293) 
Pravastatin 
(n=3302)
P-value‡
Stroke Subjects with event 
Events 
Event Rate* 
353 
589 
0.098 
338 
562 
0.091 
 
0.60 
0.62 
MI Subjects with event 
Events 
Event Rate* 
464 
538 
0.089 
354 
419 
0.068 
 
0.0002 
0.010 
HF Subjects with event 
Events 
Event Rate* 
123 
207 
0.034 
91 
133 
0.022 
 
0.010 
0.0020 
CHD Subjects with event 
Events 
Event Rate* 
958 
2286 
0.38 
800 
1838 
0.30 
 
0.0006 
0.0004 
Any CV Subjects with event 
Events 
Event Rate* 
1546 
4102 
0.68 
1398 
3436 
0.56 
 
<0.0001 
0.0020 
Non-CV Subjects with event 
Events 
Event Rate* 
2811 
17922 
2.97 
2828 
18649 
3.03 
 
0.24 
0.53 
MI: Myocardial Infarction; HF: Heart Failure; CHD: Coronary Heart Disease; CV: Cardiovascular disease.  
*Events/10 years of follow-up 
‡P-values calculated using re-randomisation tests. 
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Table 3. Subjects with events, cumulative recurrent events and event rates per 10 years of 
follow-up between randomised groups, sub-divided by day case/ non day case status. 
Event Type Statistic Placebo
(n = 3293) 
Pravastatin 
(n=3302)
P-value‡
Day cases 
CHD Subjects with event 
Events 
Event Rate* 
452 
599 
0.099 
391 
507 
0.082 
 
0.029 
0.011 
All CV Subjects with event 
Events 
Event Rate* 
661 
1018 
0.169 
594 
845 
0.137 
 
0.048 
0.34 
Non-CV Subjects with event 
Events 
Event Rate* 
2122 
8521 
1.413 
2259 
9191 
1.494 
 
0.94 
0.94 
Non day cases 
CHD Subjects with event 
Events 
Event Rate* 
849 
1687 
0.280 
713 
1331 
0.216 
 
0.0002 
0.0008 
Any CV Subjects with event 
Events 
Event Rate* 
1391 
3084 
0.512 
1234 
2591 
0.421 
 
0.0004 
0.0006 
Non CV Subjects with event 
Events 
Event Rate* 
2406 
9401 
1.559 
2431 
9458 
1.537 
 
0.54 
0.54 
MI: Myocardial Infarction; CHD: Coronary Heart Disease; CV: Cardiovascular disease.  
*Events/10 years of follow-up 
‡P-values calculated using re-randomisation tests. 
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Figure Legends: 
Figure 1. Cumulative events over the 20-year follow up period. Cumulative incidence functions 
are provided for the outcomes of death due to (a) all-causes, (b) cardiovascular disease, (c) 
coronary heart disease and (e) non-cardiovascular disease. P values determined by Cox 
proportional hazards model. 
 
Figure 2. Cumulative numbers of  hospital admissions for the outcomes of (a) cardiovascular 
disease , (b) myocardial infarction, (c) heart failure and (d) coronary revascularisation. P values 
were computed by re-randomisation tests. 
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Placebo
Pravastatin
p=0.0007 
Numbers at risk: 
Placebo              3293                 3185                3021                 2785               2501              2203    
Pravastatin         3302                 3223                3069                 2838               2598              2295
1a) All-cause mortality
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Numbers at risk: 
Placebo              3293                 3185                3021                 2785               2501              2203    
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1b) Cardiovascular mortality
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 p=0.0002 
Numbers at risk: 
Placebo              3293                 3185                3021                 2785               2501              2203    
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1c) Coronary heart disease mortality
 at Glasgow University Library on March 10, 2016http://circ.ahajournals.org/Downloaded from 
Placebo Pravastatin
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1d) Non-cardiovascular mortality
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Supplemental Table 1: Number of events (%) and hazard ratios comparing pravastatin versus 
placebo for all cause and cause-specific incident cancers. Analysis by time to first event. 
 Placebo (n=3293) 
 
Pravastatin ( n = 3302) 
All incident cancer
†
   
Events/N (%) 809 (24.6) 802  (24.3) 
Hazard Ratio (95% CI)
 ‡
 1.0 0.96 (0.87, 1.06) 
P-value
‡
  0.41 
Site-specific incident cancers
†
   
Colorectal   
Events/N (%) 139  (4.2) 127  (3.8) 
Hazard Ratio (95% CI)
 ‡
 1.0 0.87 (0.69, 1.11) 
P-value
‡
  0.27 
Lung   
Events/N (%) 197  (6.0) 178  (5.4) 
Hazard Ratio (95% CI)
 ‡ 
1.0 0.87 (0.71, 1.06) 
P-value
‡ 
 0.17 
Prostate   
Events/N (%) 167  (5.1) 185  (5.6) 
Hazard Ratio (95% CI)
 ‡ 
1.0 1.06 (0.86, 1.31) 
P-value
‡ 
 0.57 
Upper GI   
Events/N (%) 77  (2.3) 85  (2.6) 
Hazard Ratio (95% CI)
 ‡ 
1.0 1.06 (0.78, 1.45) 
P-value
‡ 
 0.70 
Urinary tract   
Events/N (%) 96  (2.9) 98  (3.0) 
Hazard Ratio (95% CI)
 ‡ 
1.0 0.99 (0.74, 1.31) 
P-value
± 
 0.93 
Other cancer   
Events/N (%) 190  (5.8) 201  (6.1) 
Hazard Ratio (95% CI)
 ‡ 
1.0 1.02 (0.84, 1.25) 
P-value
‡ 
 0.84 
*Excludes participants who died or had event of interest within trial. 
‡
Adjusted for age, body mass index, 
smoking status (current, ex-smoker, never) and deprivation (DEPCAT).  
  
Supplemental Table 2: Primary reason for non-cardiovascular hospital admissions by ICD 10 
chapter for day cases. Number of subjects with events and cumulative recurrent events.  
ICD 10 chapter Placebo (n = 3293) Pravastatin (n = 3302) 
Subjects with 
events 
Events Subjects with 
events 
Events 
A00-B99 Certain infectious and parasitic diseases 27 28 21 28 
C00-D49 Neoplasms 667 2264 687 2504 
D40-D89 Diseases of the blood and blood-forming organs 
and certain disorders involving the immune mechanism 
95 216 104 251 
E00-E90 Endocrine, nutritional and metabolic diseases 25 112 28 150 
F00-F99 Mental and behavioural disorders 13 13 9 9 
G00-G99 Diseases of the nervous system 46 58 49 86 
H00-H59 Diseases of the eye and adnexa 362 581 430 692 
H60-H95 Diseases of the ear and mastoid process 20 23 27 36 
I00-I99 Diseases of the circulatory system 0 0 0 0 
J00-J99 Diseases of the respiratory system 74 80 88 96 
K00-K93 Disease of the digestive system 990 1663 995 1791 
L00-L99 Diseases of the skin and subcutaneous tissue 228 364 220 331 
M00-M99 Diseases of the musculoskeletal system and 
connective tissue 
224 501 192 381 
N00-N99 Diseases of the genitourinary system 434 614 456 665 
Q00-Q99 Congenital malformations, deformations and 
chromosomal abnormalities 
5 5 2 2 
R00-R99 Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified 
710 954 693 907 
S00-T98 Injury, poisoning and certain other consequences 
of external causes 
100 118 116 161 
V01-Y98 External causes of morbidity and mortality 96 136 92 138 
Z00-Z99 Factors influencing health status and contact 
with health services 
448 820 445 997 
Uncoded 6 6 1 1 
 
  
Supplemental Table 3: Primary reason for non cardiovascular hospital admissions by ICD 10 
chapter for non-day cases. Number of subjects with events and cumulative recurrent events.  
ICD 10 chapter Placebo (n = 3293) Pravastatin (n = 3302) 
Subjects with 
events 
Events Subjects with 
events 
Events 
A00-B99 Certain infectious and parasitic diseases 87 94 59 73 
C00-D49 Neoplasms 728 1904 734 1985 
D40-D89 Diseases of the blood and blood-forming organs 
and certain disorders involving the immune mechanism 
82 102 79 109 
E00-E90 Endocrine, nutritional and metabolic diseases 72 90 62 81 
F00-F99 Mental and behavioural disorders 64 74 50 68 
G00-G99 Diseases of the nervous system 123 177 113 157 
H00-H59 Diseases of the eye and adnexa 135 181 125 175 
H60-H95 Diseases of the ear and mastoid process 39 46 47 55 
I00-I99 Diseases of the circulatory system 2 2 0 0 
J00-J99 Diseases of the respiratory system 482 906 482 813 
K00-K93 Disease of the digestive system 786 1281 854 1411 
L00-L99 Diseases of the skin and subcutaneous tissue 119 148 127 168 
M00-M99 Diseases of the musculoskeletal system and 
connective tissue 
491 771 552 828 
N00-N99 Diseases of the genitourinary system 569 891 537 863 
Q00-Q99 Congenital malformations, deformations and 
chromosomal abnormalities 
17 19 11 12 
R00-R99 Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified 
1041 1962 1004 1826 
S00-T98 Injury, poisoning and certain other consequences 
of external causes 
478 614 470 659 
V01-Y98 External causes of morbidity and mortality 30 33 37 47 
Z00-Z99 Factors influencing health status and contact 
with health services 
188 241 179 247 
Uncoded 9 11 5 5 
 
  
Supplemental Figure 1: Cumulative incidence functions for cancer mortality and incident cancer 
 
Placebo
Pravastatin
p=0.49
Numbers at risk:
Placebo              3293                 3185                3021                 2785               2501              2203 
Pravastatin         3302                 3223                3069                 2838               2598              2295
1a) Cancer Mortality
Placebo
Pravastatin
p=0.41
Numbers at risk:
Placebo              3293                3138                  2923                2647                2317               1448  
Pravastatin         3302                3172                  2952                2658                2377               1548
1b) Cancer Incidence
 
 
 
 
  
Supplemental Figure 2: Cumulative hospital admissions including recurrent events involving 
coronary heart disease, stroke and non cardiovascular causes  
Placebo
Pravastatin
2a) Cumulative hospitalisations 
(coronary heart disease)
 
Placebo
Pravastatin
2b) Cumulative hospitalisations 
(stroke)
p=0.60
 
 
Placebo
Pravastatin
2c) Cumulative hospitalisations 
(non cardiovascular)
p = 0.24 
 
Supplemental Figure legends 
 
Figure 1 Cumulative incidence functions for all-cancer mortality and morbidity. P values 
determined by Cox proportional hazards model. 
 
 
Figure 2. Cumulative numbers of  hospital admissions for the outcomes of (a) coronary heart 
disease, (b) stroke, and (c) all non-cardiovascular causes. P values were computed by re-
randomisation tests. 
 
